Search

Your search keyword '"Encephalopathy -- Drug therapy"' showing total 3 results
Start Over Descriptor "Encephalopathy -- Drug therapy" Publisher business wire, inc.
3 results on '"Encephalopathy -- Drug therapy"'

1. USA FDA Grants Fast Track Designation to ReAlta Life Sciences' Lead Compound RLS-0071 for the Treatment of Hypoxic-Ischemic Encephalopathy In Neonates

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Infants (Newborn) -- Drug therapy, Business, Business, international
Abstract

RLS-0071 is ReAlta's lead dual-action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases NORFOLK, Va. -- ReAlta [...]

Published
2022

2. ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, Business, international
Abstract

RLS-0071 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that the [...]

Published
2020

3. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Insurance industry, Media executives, Newborn infants, Diseases, Business, Business, international
Abstract

PIC1 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that U.S. [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results